The Use of Palmitoylethanolamide in the Treatment of Long COVID: A Real-Life Retrospective Cohort Study

Raciti L, De Luca R, Raciti G, Arcadi FA, Calabrò RS. Medical Sciences, 2022; 10(3):37.

Observational studyHumans

Design

Observational study

Subjects

33 patients with long COVID at one centre

Dose used in the study

600 mg twice a day

Duration

About 3 months

What was measured

The Post-COVID-19 Functional Status scale, before and after treatment

What the authors reported

This retrospective cohort study found:

• Functional status scores improved significantly.
• In patients who had not been hospitalised and did not smoke, scores fell from 2.6 to 0.4.
• In hospitalised smokers they fell from 3.8 to 2.2.
• Smoking was linked to worse outcomes, with an odds ratio of 8.13.
• No side effects were reported.

Limits of this study

A retrospective before-and-after study with no control group. The authors state that spontaneous recovery cannot be excluded, and long COVID often improves with time. 33 patients. The study reported no funding, and the authors declared no conflicts.

Source

PubMed 35893119 · doi:10.3390/medsci10030037

Entry checked against the abstract on PubMed, and the full text at the publisher (MDPI) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.